Immunoassay for serum glutamine synthetase in serum: development, reference values, and preliminary study in dementias.

candidate genetic risk factor for vascular disease. A common mutation in methylenetetrahydrafolate reductase. Nat Genet 1995;10:111–3. 9. Virgos C, Joven J, Simo JM, Vilella E, Camps J, Arcelus R, et al. Homocyst(e)ine and the C677T mutation of methylenetetrahydrofolate reductase in survivors of premature myocardial infarction. Clin Biochem 2000;33:509– 12. 10. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545–8. 11. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993;3:73–6. 12. Simó JM, Castellano I, Ferré N, Joven J, Camps J. Evaluation of a homogenous assay for high-density lipoprotein cholesterol: limitations in patients with cardiovascular, renal and hepatic disorders. Clin Chem 1998; 44:1233–41. 13. Ferré N, Camps J, Cabré M, Paul A, Joven J. Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis. Metabolism 2001;50:997–1000. 14. Werstruck GH, Lentz SR, Dayal S, Hossain GS, Sood SK, Shi YY, et al. Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Invest 2001;107:1263–73. 15. Loktionov A, Vorster H, O’Neill IK, Nell T, Singham SA, Runswick SA, et al. Apolipoprotein E and methylenetetrahydrafolate reductase genetic polymorphisms in relation to other risk factors for cardiovascular disease in UK Caucasians and Black South Africans. Atherosclerosis 1999;145: 125–35. 16. Qujeq D, Omran TS, Hosini L. Correlation between total homocysteine, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in the serum of patients with myocardial infarction. Clin Biochem 2001;34: 97–101. 17. Leviev I, James RW. Promotor polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 2000;20:516–21. 18. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, LaDu BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. J Clin Invest 1998;101:1581–90. 19. Schmidt H, Schmidt R, Niederkorn K, Gradert A, Schumacher M, Watzinger N, et al. Paraoxonase PON1 polymorphism Leu-Met54 is associated with carotid atherosclerosis. Stroke 1998;29:2043–8. 20. Salonen JT, Malin R, Tuomainen T-P, Nyyssönen K, Lakka TA, Lehtimäki T. Polymorphism in high density lipoprotein paraoxonase gene and risk of acute myocardial infarction in men: prospective nested case-control study. BMJ 1999;319:487–9. 21. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21:473–80.